Manufacturer
INTAS PHARM LTD
Contents
Mycophenolic acid
Indication
Prophylaxis of cardiac graft rejection and Prophylaxis of acute renal graft rejection.
Instruction
Prophylaxis of cardiac graft rejection
Adult: As mycophenolate mofetil: 1.5 g bid starting within 5 days after transplantation.
Prophylaxis of acute renal graft rejection
Adult: As mycophenolate mofetil: 1 g bid starting within 72 hr of transplantation. Max: 2 g/day. As mycophenolic acid: 720 mg bid.
Child: As mycophenolate mofetil: 2-18 yr: 600 mg/m2 bid. Max: 1 g bid. BSA 1.25-1.5 m2: 750 mg bid; >1.5 m2: 1 g bid. As mycophenolic acid: 5-16 yr: 400 mg/m2 bid (max: 720 mg bid). BSA 1.19-1.58 m2: 540 mg bid (max: 1,080 mg); >1.58 m2: 720 mg bid (max: 1,440 mg).
Elderly: As mycophenolic acid: Max: 720 mg bid.
Drug interaction
Increased plasma levels of both drugs when combined with aciclovir, valaciclovir, ganciclovir and valganciclovir. Reduced absorption with colestyramine, magnesium- and aluminium hydroxide-containing products, sevelamer and other calcium-free phosphate binders. Reduced plasma levels with ciclosporin, metronidazole, quinolones, rifamycins. May reduce plasma levels of progestins; may reduce efficacy of oral contraceptives. Increased plasma levels with probenecid. May reduce efficacy of live vaccines.
Malaysia
